Cord blood transplantation has demonstrated a neural S.-Z. Lin,* W.-C. Shyu,* and H. Li † protective effect in neurodegenerative diseases and ischemic attacks. Furthermore, cord blood possesses di-*Neuro-Medical Scientific Center, Tzu-Chi Buddhist minished immunostimulatory activity, the basis of which General Hospital, Tzu-Chi University, Hualien, Taiwan has not been defined. Because neural damage may be †Institutes of Biochemistry, National Yang-Ming Unipotentiated by immune activation of inflammatory casversity, Taipei, Taiwan cades, we examined the effects of cord blood-derived mesenchymal stem cells (MSCs) on immune responses.
Stroke is a leading cause of death and disability worldwide; however, no effective treatment currently We isolated and characterized a population of cord blood MSCs that maintained pluripotency in culture.
exists. A new therapy for stroke was tested in cells and then animals. Rats receiving subcutaneous granulocyte After 7 days of incubation in serum-free media supplemented with neural differentiation factors (Neurobasal TM colony stimulating factor (G-CSF) showed less cerebral infarction, as evaluated by magnetic resonance imaging medium), cord blood MSCs expressed the neural cell surface antigen A2B5, the neurofilament polypeptide (MRI), and improved motor performance following right middle cerebral artery (MCA) ligation than vehicle-NF200, the oligodendrocyte marker 04, and intermediate filament proteins characteristic of neural differentiation treated control rats. Subcutaneous administration of G-CSF enhanced the availability of circulating hematopoi-(nestin and vimentin). The cultured cells also expressed the astrocyte marker GFAP, as well as the neural pro-etic stem cells (HSCs) to the brain and their capacity for neurogenesis and angiogenesis in cerebral ischemic rats. genitor marker TUJ-1. Progeny generated in the absence of differentiation were strongly adherent, did not express G-CSF-induced increases in bone marrow cell mobilization and targeting to the brain reduce the volume of ce-CD34, CD45, CD3, and CD19 antigens, and did not generate hematopoietic colonies in methylcellulose.
rebral infarction and improve neural plasticity and vascularization. However, cultured cord blood MSCs possessed a remarkable ability to support the proliferation as well as
We were interested in examining the feasibility, safety, and efficacy of using G-CSF to treat patients suf-the differentiation of hematopoietic cells in vitro. Supernatants from cultured cord blood MSCs promoted sur-fering from acute stroke. We recruited patients with acute cerebral infarction (middle cerebral artery territory vival of peripheral blood mononuclear cells, cultured under conditions designed to induce cell stress and limit as documented on the admission MRI) within 7 days of onset who had initial scores on the National Institute of protein synthesis. To examine immune modulation by MSCs on humoral immune responses, cord blood MSCs Health stroke scale (NIHSS) of between 9 and 20. After determining eligibility we randomly assigned the first 10 were cocultured with murine splenocytes. While spleen cells from normal C57Bl/6 mice exhibited a prominent patients to the G-CSF-treated group (n = 7) and the control group (n = 3). Random assignment was conducted IgM response after immunization with the T-cell-dependent antigen, SRBCs, this response was significantly de-by a central study assignment person who was unfamil-276 ABSTRACTS iar with the patients. The G-CSF-treated group received errant. Haloperidol also increases extracellular levels of striatal glutamate and alters the kinetics of its transport, subcutaneous G-CSF injections (15 µg/kg per day) for 5 days. We used the following clinical scales to assess pointing to a role for glutamate in the neuronal damage. The loss of dopamine from the nigrostriatal pathway, as neurological recovery: National Institute of Health Stroke Scale (NIHSS, score range 28 to 0), European Stroke occurs in Parkinson's disease (PD), is also accompanied by changes in MSN structure and aberrant motor func-Scale (ESS, score range 0 to 100), ESS Motor Subscale (EMS, score range 0 to 58), and Barthel Index (BI, score tion. Although the structural changes and behavior differ from those seen after haloperidol, they could also reflect range 0 to 100). In this trial, all clinical information and evaluation data from each patient were assessed blindly damage due to altered glutamate flow. In a chronic model of PD, which is created by treating mice with by the data recorders and clinicians.
All patients were followed for 12 full months. No MPTP and probenecid (MPTP/p), changes in MSN structure and motor behaviors are interestingly not ac-severe adverse effects were seen in the G-CSF-treated patients, who had received subcutaneous G-CSF injec-companied by a change in striatal extracellular glutamate, its synaptic localization, or transport kinetics, at tions (15 µg/kg) for 5 consecutive days immediately after an episode of acute cerebral infarction. The results least when measured a few short weeks after toxin administration. This model also shows a significant striatal of neurological scoring showed a significant increase on NIHSS (59%), ESS (33%), EMG (106%), and BI (120%) gliosis at the same time point. Astrocytes maintain low levels of synaptically released glutamate via the glial scales in the G-CSF-treated group compared with the control group. In a functional activity assessment con-glutamate transporters (GLT-1), and an increase in GLT-1 numbers could enhance glutamate uptake. Even ducted with 18 FDG-PET, significant improvement in cerebral uptake of FDG surrounding the ischemic core was though the size and number of astrocytes have risen significantly, the density of GLT-1 per striatal astrocyte is apparent in the G-CSF-treated group compared with the control group. The relationship between metabolic activ-strikingly reduced and, as a result, GLT-1 function may be affected. Thus, time-dependent changes in extracellu-ity and the clinical motor stroke scale (EMS) was found to correlate closely upon examination by simple linear lar glutamate would contribute to the progressive nature of the MSN structural damage. correlation analysis. Furthermore, we are now approved to transplant stem cells directly into the brain of old stroke patients.
Neural Progenitor Cells Enhance Synaptogenesis and Neurite Outgrowth in Vitro
This new therapy for stroke patients is an example of translational neuroscience demonstrating a successful harmony interaction in basic and clinical researches.
J. Liauw and G. Steinberg Once the same vision and purpose is established, scientists and clinicians should work together with unity, har-Stanford University School of Medicine and Neurosurgery, California, USA mony, fellowship, and cooperation. They would have fruitful results.
Selective disruption of synapses characteristically follows ischemic brain injury. An aim of neural stem Structural Plasticity and Striatal Glutamate Function cell therapy, therefore, is to restore endogenous synaptic connections that could augment functional recovery after ischemia. Here we report that mouse neural pro-G. Meredith genitor cells (mNPCs) induced a sevenfold increase in functional synapses formed by purely neuronal retinal Department of Cellular and Molecular Pharmacology, Rosalind Franklin University of Medicine and Science, ganglion cells (RGCs) in culture. Coincubation of mNPCs with RGCs also increased neurite outgrowth between Chicago, IL, USA neurons. Our results provide evidence that NPCs secrete proteins that enhance synaptogenesis in a pure neuronal The medium spiny neuron (MSN) in the striatum responds structurally to prolonged changes in dopamine culture system. This result is similar to the thrombospondin-mediated increase in synaptogenesis previously transmission by altering the shape or number of their dendrites and spines. Chronic treatment of rats with a reported when astrocytes are grown in culture with RGCs. We have shown that mNPCs also secrete throm-D2 antagonist, such as haloperidol, dramatically changes MSN structure and, in addition, reorganizes certain stria-bospondins (TSP-1 and TSP-2). These data suggest that thrombospondins may be an important contributor to the tal synapses. However, these changes only occur if the animals develop vacuous chewing, a form of oral dyski-NPC-mediated increase in synaptogenesis seen in pure neuronal RGC cultures. nesia, suggesting that this morphological plasticity is ab- Dyskinesia is a major complication of L-DOPA treatment in Parkinson's disease, but its underlying cellular Previous studies have indicated that the nigrostriatal dopaminergic (DA) pathway can be reconstructed in and molecular mechanisms are poorly understood. We have characterized models of L-DOPA-induced dyskine-hemiparkinsonian rats with a bridge transplantation technique involving fetal ventral mesecephalic trans-sia in rats and mice. Dopamine (DA) denervating lesions are performed by unilateral injection of 6-hydroxydopa-plants and glial cell line-derived neurotrophic factor. In this study, we examined if the nigrostriatal pathway can mine (6-OHDA) in the nigrostriatal pathway. The animals are then treated with daily doses of L-DOPA that be restored by combining peripheral nervous tissue with the fetal ventral mesencephalon transplants. Adult rats are sufficient to ameliorate akinetic features without inducing overt signs of dyskinesia upon their first admin-were injected with 6-hydroxydopamine (6-OHDA) into left median forebrain bundle; those with severe rota-istration. During a few weeks of treatment, most animals develop abnormal involuntary movements (AIMs), tional behavior, which has been previously shown to have complete DA denervation, were used for transplant which mainly affect the side of the body contralateral to the lesion. These movements are not seen in animals that treatments. One month after the lesion, fetal ventral mesencephalic cells (VM) were transplanted into the ni-receive chronic treatment with long-acting DA agonists. The severity of L-DOPA-induced rodent AIMs is signifi-gral region followed by nigral-striatal grafting of peripheral nerves as a bridge. The bridging nerves (sciatic cantly reduced by the acute administration of compounds that have antidyskinetic efficacy in parkinsonian or intercostals) were pretreated with basic fibrous growth factor (bFGF+) or Hank's vehicle (bFGF−). We primates. We are using these rodent models in order to identify biochemical and molecular changes that are as-found that (a) animals receiving transplants of VM and bFGF+ nerve had a reduction in rotational behavior, and sociated with a dyskinetic motor response to L-DOPA. The lecture will present the main findings that have (b) animals receiving bFGF+ nerve bridge only had a partial improvement in rotation. Reinnervation of tyro-emerged from these studies. The proposed pathophysiological model will attempt to link alterations of striatal sine hydroxylase (TH) immunoreactive fibers the striatum was found in both of the above groups with more dopamine release with postsynaptic perturbations of intracellular signaling and gene expression, finally leading innervation in the former than in the latter. No TH-ir fibers in lesioned striatum or reductions in rotational be-to an abnormal output from the basal ganglia nuclei.
